Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

ABBVBullishAnalyst Target Updateanalyst

Medium materiality6/10

Barclays raises AbbVie price target to $325 from $300

Oct 21, 2026, 7:30 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

The meaningful target increase supports a bullish view, but analyst targets remain opinions and do not establish a near-term catalyst.

AI summary

What happened, with direct paths to the underlying reporting

Barclays raised its ABBV price target by about 8% to $325, roughly 12% above the posted price of $289.

Barclays raised its target from $300 to $325.
The new target implies about 12% upside from the posted price.

Key facts

01
Target: $325
02
Posted price: $289
03
Analyst firm: Barclays

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Barclays raises AbbVie price target to $325 from $300

Key facts

AbbVie Stock Rises on FDA Breakthrough Designations for Telisotuzumab Adizutecan

AbbVie-Genmab lymphoma combo shows efficacy in late-stage trial

AbbVie Gains on JUVMO FDA Approval With Near-Term Upside Potential

FDA approves AbbVie’s Juvmo, a potential long-term Parkinson’s growth driver.